Prezista (darunavir) / J&J 
Welcome,         Profile    Billing    Logout  
 32 Diseases   11 Trials   11 Trials   1696 News 


«12345678910111213...2021»
  • ||||||||||  Prezista (darunavir) / J&J
    The HIV Protease Inhibitor Darunavir Restores Autophagy in Kidneys of Diabetic Mice (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3597;    
    Our data suggest that DRV may protect against DKD via normalization of autophagic flux. Since reducing albuminuria may affect autophagy in tubular cells, future studies will determine whether the effect of DRV upon autophagy is independent of its effects on albuminuria.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare
    Clinical experience using dolutegravir + lamivudine in Glasgow () -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_256;    
    Most switches were to reduce perceived cardiovascular risk or avoid DDIs. DTG+LAM appears well tolerated and effective in this real-world setting.
  • ||||||||||  Prezista (darunavir) / J&J, Pifeltro (doravirine) / Merck (MSD)
    Transmitted drug resistance in Spain (CoRIS) patients during 2019 to 2021 (Virtual) -  Oct 4, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_182;    
    As in previous years, the highest prevalence of transmitted resistance occurred for NNRTIs, with doravirine being the drug in this family with the lowest levels of TDR. Transmitted resistance to PIs, INIs, and 3TC/FTC continues at very low levels, with no patient presenting full resistance to second-generation integrase inhibitors or darunavir in 2021.
  • ||||||||||  Anti-retroviral repurposing for treatment of glioblastoma (West/Central Hall) -  Sep 28, 2022 - Abstract #SNO2022SNO_659;    
    We identified six potential antiretrovirals among several drug classes with significant anti-glioma activity: abacavir (ABC), lamivudine (LMV), raltegravir (RLT), darunavir (DAR), indinavir (IND), and etravirine (ETV)...Synergy assessment of ETV with standard of care temozolomide (TMZ) demonstrated that these drugs work independently of one another (Bliss score of -0.39 and -0.83 in GBM 28 and GBM 43, respectively)...Overall, several antiretroviral drugs could be repositioned for glioblastoma therapy. Given its ideal therapeutic index and ability to penetrate the blood-brain barrier, ETV may be a promising candidate for future clinical trials in neuro-oncology.
  • ||||||||||  Prezista (darunavir) / J&J
    Preclinical, Journal:  Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model. (Pubmed Central) -  Sep 24, 2022   
    In a previous in vivo study in the macaque model, we demonstrated increased MRP2 expression following intravaginal stimulation with darunavir which may further increase drug uptake. Stimulation with inflammatory modulators had no effect on drug permeability across HEC-1A barrier epithelium but, in the VK2/E6E7 vaginal cell line, increased expression of both efflux and uptake drug transporters which may influence darunavir disposition.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Inflammation and Intracellular Exposure of Dolutegravir, Darunavir, Tenofovir and Emtricitabine in People living with HIV. (Pubmed Central) -  Sep 21, 2022   
    In patients reporting subclinical sleep disturbances without insomnia, switching from dolutegravir/lamivudine/abacavir to darunavir/cobicistat/emtricitabine/tenofovir alafenamide was associated with better sleep quality and improvements in mood and NS. Our preliminary data support the hypothesis of lower DRV and DTG IC concentrations and lower TFV plasma exposure in patients with higher plasma IM suggesting an interplay between HIV drug penetration and persistent inflammation in cART-treated HIV-positive patients.
  • ||||||||||  Prezista (darunavir) / J&J
    Use of preventive measures for cardiovascular disease in people living with HIV () -  Sep 6, 2022 - Abstract #HIVGlasgow2022HIV_Glasgow_36;    
    Despite an increased proportion of individuals at very high estimated CVD risk, CVD preventive measures were underused in RESPOND. Our findings call for greater awareness of management guidelines for CVD risk factors in PLWHIV.
  • ||||||||||  Trial primary completion date:  HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) -  Aug 16, 2022   
    P1,  N=200, Recruiting, 
    The administration of specific HAART (NRTIs and novel protease inhibitors) in HIV patients had a notable improvement in the CD4+ cell count and viral load with significant age and gender disparity. Trial primary completion date: Aug 2022 --> Feb 2023
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Integrated bioinformatics-cheminformatics approach towards locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro. (Pubmed Central) -  Aug 11, 2022   
    The MD simulation (RMSD, RMSF, Rg, H-bond, MM/PBSA binding energy) illustrated that the 8-hydroxymanzamine exhibits a static thermodynamic feature than the other two complexes. The predicted physicochemical, toxicity, pharmacokinetics and drug-likeness profiles also revealed that the 8-hydroxymanzamine could be used as a potential lead candidate individually and/ or synergistically with darunavir or lopinavir to combat SARS-CoV-2 infection after some pharmacological validation.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Bis(thio)carbohydrazone Luminogens with AIEE and ACQ Features and Their In Silico Investigations with SARS-CoV-2. (Pubmed Central) -  Aug 10, 2022   
    Both the thiocarbohydrazones and the carbohydrazones, however, exhibit better binding potential at the active sites than that of some of the repurposed drugs such as chloroquine, hydroxychloroquine, lopinavir, ritonavir, darunavir and remdesivir. Also, the carbohydrazone HL can be a better bioprobe compared to HL as the former is found to have better binding potential with SARS-CoV-2 spike glycoprotein along with AIEE feature.
  • ||||||||||  Prezista (darunavir) / J&J, dolutegravir/lamivudine/tenofovir disoproxil fumarate / Cipla, Laurus Labs, Aurobindo, Mylan, Hetero, Macleods
    Clinical, Retrospective data, Clinical Trial,Phase III, Journal:  Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of DEFT. (Pubmed Central) -  Aug 9, 2022   
    At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir...Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD)...The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The DEFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART.
  • ||||||||||  Prezista (darunavir) / J&J
    Preclinical, Journal:  Theaflavin 3-gallate inhibits the main protease (M) of SARS-CoV-2 and reduces its count in vitro. (Pubmed Central) -  Aug 7, 2022   
    Treatment of SARS-CoV-2 (Indian/a3i clade/2020 isolate) with 200 μM of theaflavin 3-gallate in vitro using Vero cells and quantifying viral transcripts demonstrated reduction of viral count by 75% (viral particles reduced from Log10 to Log10). Overall, our findings suggest that theaflavin 3-gallate effectively targets the M thus limiting the replication of the SARS-CoV-2 virus in vitro.
  • ||||||||||  Prezista (darunavir) / J&J
    Journal:  Improving Drug Sensitivity of HIV-1 Protease Inhibitors by Restriction of Cellular Efflux System in a Fission Yeast Model. (Pubmed Central) -  Jul 29, 2022   
    Three different methods affecting drug uptakes were tested using an FDA-approved HIV-1 protease inhibitor (PI) drug Darunavir (DRV)...A comparison of nine FDA-approved HIV-1 PI drugs between the wild-type RE294 strain and the mutant PR836 strain showed marked enhancement of the drug sensitivities ranging from an increase of 0.56 log to 2.48 logs. Therefore, restricting cellular efflux through the adaption of the described fission yeast mutant strain enhances the drug sensitivity, reduces the amount of drug used, and increases the chance of success in future drug discovery.
  • ||||||||||  Review, Journal:  Approved HIV reverse transcriptase inhibitors in the past decade. (Pubmed Central) -  Jul 20, 2022   
    Novel RT inhibitors such as islatravir, MK-8504, MK-8507, MK8583, IQP-0528, and MIV-150 will be also highlighted. Future development may focus on the new generation of novel antiretroviral inhibitors with higher bioavailability, longer elimination half-life, more favorable side-effect profiles, fewer drug-drug interactions, and higher activities against circulating drug-resistant strains.
  • ||||||||||  Tavalisse (fostamatinib) / Rigel, Kissei
    Journal:  Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/ R406 a potential candidate? (Pubmed Central) -  Jun 22, 2022   
    On the other hand, several vaccines like Pfizer-BioNTech, Moderna, Johnson & Johnson's Janssen, Sputnik V, Covishield, Covaxin, etc., also evolved from the research study...Validation using subsequent docking study has also been performed on COVID-19 potential drugs with the available major COVID-19 crystal structures whose PDB IDs are: 6LU7, 6M2Q, 6W9C, 6M0J, 6M71 and 6VXX. Our computational study and docking results suggest that Fostamatinib (R406 as its active promoiety) may also be considered as one of the potential candidates for further clinical trials in pursuit to counter the spread of COVID-19.
  • ||||||||||  atazanavir / Generic mfg.
    Review, Journal:  Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review. (Pubmed Central) -  Jun 10, 2022   
    Atazanavir/ritonavir is recommended as a preferred second-line antiretroviral regimen in children older than 3 months, alternatively to lopinavir/ritonavir...The comparative cohort compared atazanavir to darunavir, with few grade 3-4 adverse events, except transient hyperbilirubinemia, occurring in half (92/188) of the atazanavir patients...The use of atazanavir/ritonavir in children and adolescents needs further investigation, but remains a suitable option for a preferred second-line antiretroviral regimen. CRD42022309230.
  • ||||||||||  Prezista (darunavir) / J&J, soticlestat (TAK-935) / Takeda, Entereg (alvimopan) / Merck (MSD)
    Journal:  Determination of Acyl-, O-, and N-Glucuronide using Chemical Derivatization Coupled with Liquid Chromatography - High Resolution Mass Spectrometry. (Pubmed Central) -  May 20, 2022   
    Lastly, this approach was successfully used to elucidate the definitive structure of a clinically observed metabolite, soticlestat O-glucuronide...The type of glucuronidation information is particularly useful for a drug candidate containing carboxyl group(s), which can form reactive acyl-glucuronides. Additionally, the method can potentially be used for the definitive structure elucidation for a compound containing a single carboxyl, hydroxyl, or amino group even when multiple types of functional groups are present for glucuronidation.